Acute promyelocytic leukemia harbouring rare FLT3-TKD and WT1 mutations: A case report

Liu,Ting‑Ting; Zeng,Ke; Wang,Lin; Liu,Ting; Niu,Ting

doi:10.3892/ol.2015.3437

Acute promyelocytic leukemia harbouring rare FLT3-TKD and WT1 mutations: A case report

Authors:
- Ting‑Ting Liu
- Ke Zeng
- Lin Wang
- Ting Liu
- Ting Niu
View Affiliations

Affiliations: Department of Hematology and Research Laboratory of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: June 30, 2015 https://doi.org/10.3892/ol.2015.3437
Pages: 1858-1862

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The involvement of the central nervous system (CNS) is rare in acute promyelocytic leukemia (APL). The present study reported the case of a 34-year-old male patient with APL that possessed a rare point mutation (p.Asn841Gly, c.2523C>A) in the tyrosine kinase domain of the FMS‑like tyrosine kinase 3 (FLT3) gene and a novel Wilm tumor gene mutation (c.1209_1210insT/p.K404X). The patient suffered central nervous system and systemic relapses twice during systemic and intrathecal chemotherapy. At present, the patient is undergoing alternative induction and consolidation therapies, including the administration of FLT3 inhibitor, tetraarsenic tetrasulfide and novel cytotherapy, and is prepared for salvage allogeneic hematopoietic stem cell transplantion (allo‑HSCT). The present study indicated that patients with APL that are at a high risk of relapse and unfavorable gene mutations should receive immediate allo-HSCT, whenever possible.

View Figures

View References

1	Wang ZY and Chen Z: Acute promyelocytic leukemia: From highly fatal to highly curable. Blood. 111:2505–2515. 2008. View Article : Google Scholar : PubMed/NCBI
2	de Botton S, Sanz MA, Chevret S, Dombret H, Martin G, Thomas X, Mediavilla JD, Recher C, et al European APL Group; PETHEMA Group: Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia. 20:35–41. 2006. View Article : Google Scholar : PubMed/NCBI
3	Colovic N, Tomin D, Vidovic A, et al: Central nervous system relapse in CD56⁺, FLT3/ITD⁺ promyelocytic leukemia. Med Oncol. 29:260–262. 2012. View Article : Google Scholar : PubMed/NCBI
4	Wiernik PH, De Bellis R, Muxi P and Dutcher JP: Extramedullary acute promyelocytic leukemia. Cancer. 78:2510–2514. 1996. View Article : Google Scholar : PubMed/NCBI
5	Ko BS, Tang JL, Chen YC, et al: Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia - the occurrence of retinoic acid syndrome is a risk factor. Leukemia. 13:1406–1408. 1999. View Article : Google Scholar : PubMed/NCBI
6	Specchia G, Lo Coco F, Vignetti M, et al: Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: A report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol. 19:4023–4028. 2001.PubMed/NCBI
7	Ohno R, Asou N and Ohnishi K: Treatment of acute promyelocytic leukemia: Strategy toward further increase of cure rate. Leukemia. 17:1454–1463. 2003. View Article : Google Scholar : PubMed/NCBI
8	Callens C, Chevret S, Cayuela JM, et al European APL Group: Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): A retrospective study from the European APL Group. Leukemia. 19:1153–1160. 2005. View Article : Google Scholar : PubMed/NCBI
9	Kuchenbauer F, Schoch C, Kern W, et al: Impact of FLT3 mutations and promyelocytic leukemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukemia. Br J Haematol. 130:196–202. 2005. View Article : Google Scholar : PubMed/NCBI
10	Barragán E, Montesinos P, Camos M, et al PETHEMA Group; HOVON Group: Prognostic value of FLT3-mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica. 96:1470–1477. 2011. View Article : Google Scholar : PubMed/NCBI
11	Chillón MC, Santamaría C, García-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Marín L, Caballero MD, Vidriales MB, Ramos F, Bernal T, et al: Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. Haematolgica. 95:745–751. 2010. View Article : Google Scholar
12	Gale RE, Hills R, Pizzey AR, Kottaridis PD, Swirsky D, Gilkes AF, Nugent E, Mills KI, Wheatley K, Solomon E, et al NCRI Adult Leukaemia Working Party: Relationship between FLT3 mutation status, biologic characteristics and response to targeted therapy in acute promyelocytic leukemia. Blood. 106:3768–3776. 2005. View Article : Google Scholar : PubMed/NCBI
13	Schnittger S, Bacher U, Haferlach C, Kern W, Alpermann T and Haferlach T: Clinical impact of FTL3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA. Haematologica. 96:1799–1807. 2011. View Article : Google Scholar : PubMed/NCBI
14	Bacher U, Haferlach C, Kern W, Haferlach T and Schnittger S: Prognostic relevance of FTL3-TKD mutations in AML: The combination matters - an analysis of 3082 patients. Blood. 111:2527–2737. 2008. View Article : Google Scholar : PubMed/NCBI
15	Gaur GC, Ramadan SM, Cicconi L, Noguera NI, Luna I, Such E, et al: Analysis of mutational status, SNP rs16754, and expression levels of Wilms tumor 1 (WT1) gene in acute promyelocytic leukemia. Ann Hematol. 91:1855–1860. 2012. View Article : Google Scholar : PubMed/NCBI
16	Hou HA, Huang TC, Lin LI, Liu CY, Chen CY, Chou WC, Tang JL, Tseng MH, Huang CF, Chiang YC, et al: WT1 mutation in 470 adult patients with acute myeloid leukemia: Stability during disease evolution and implication of its incorporation into a survival scoring system. Blood. 115:5222–5231. 2010. View Article : Google Scholar : PubMed/NCBI
17	Shih LY, Kuo MC, Liang DC, Huang CF, Lin TL, Wu JH, Wang PN, Dunn P and Lai CL: Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer. 98:1206–1216. 2003. View Article : Google Scholar : PubMed/NCBI
18	Kutny MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J, Larson RA, Powell BL, Stock W, Willman CL, et al: FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 59:662–667. 2012. View Article : Google Scholar : PubMed/NCBI
19	Tashiro H, Shirasaki R, Oka Y, Sugao T, Mizutani-Noguchi M, Yamamoto T, Akiyama N, Kawasugi K and Shirafuji N: FLT3 internal tandem duplication is associated with a high relapse rate and central nervous system involvement in acute promyelocytic leukemia cases: Single institutional analysis. Eur J Haematol. 86:272–273. 2011. View Article : Google Scholar : PubMed/NCBI
20	Montesinos P, Díaz-Mediavilla J, Debén G, Prates V, Tormo M, Rubio V, Pérez I, Fernández I, Viguria M, Rayón C, et al: Central nervous system involvement at ﬁrst relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica. 94:1242–1249. 2009. View Article : Google Scholar : PubMed/NCBI
21	Nagai S, Nannya Y, Arai S, Yoshiki Y, Takahashi T and Kurokawa M: Molecular or cytogenetic monitoring and preemptive therapy for central nervous system relapse of acute promyelocytic leukemia. Haematologica. 95:169–171. 2010. View Article : Google Scholar : PubMed/NCBI
22	Bae SH, Ryoo HM, Cho HS, Lee JL, Lee KH and Hyun MS: Meningeal relapse in a patient with acute promyelocytic leukemia: A case report and review of the literature. J Korean Med Sci. 19:311–314. 2004. View Article : Google Scholar : PubMed/NCBI